5 Top Gainers In Healthcare Sector (OASM, ARTL, NEOS...)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Artelo Biosciences Inc. (ARTL)

Artelo is a clinical-stage biopharmaceutical company with a portfolio of novel therapeutic candidates targeting the endocannabinoid system.

Gained 21.87% to close Tuesday's (July 9) trading at $4.57.

News: No news

Recent event:

On June 21, 2019, the Company priced its public offering of 1.3 million units at $6.15 per unit. The Company implemented a reverse split of its common stock at a ratio of 1-for-8, and the shares were uplisted to the Nasdaq the same day.

2. Neos Therapeutics Inc. (NEOS)

Gained 21.01% to close Tuesday's trading at $1.67.

News: No news

Recent event:

On May 9, 2019, the Company reported financial results for the first quarter ended March 31, 2019.

The net loss for the three months ended March 31, 2019, shrunk to $7.6 million or $0.15 per share on total product revenue of $14.6 million. This compared with a net loss of $14.4 million or $0.50 per share and total product revenue of $10.7 million for the same period in 2018.

Near-term Catalyst:

-- A phase I trial of NT0502 for the treatment of sialorrhea is expected to commence in the first half of 2020.

3. MYOS RENS Technology Inc. (MYOS)

MYOS RENS is an advanced nutrition company and the owner of Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk that helps build lean muscle.

Gained 15.71% to close Tuesday's trading at $1.62.

News: No news

Recent event:

On May 8, 2019, the Company reported its financial results for the first quarter ended March 31, 2019.

Net loss narrowed to $975 thousand or $0.13 per share on net revenues of $149 thousand. This compared with a net loss of $1.21 million or $0.19 per share on net revenues of $57 thousand in the year-ago quarter.

4. Oasmia Pharmaceutical AB (publ) (OASM)

Gained 14.04% to close Tuesday's trading at $2.60.

News: The Company announced that it has ended the engagement and cooperation with the former executive chairman Julian Aleksov without any further remuneration.

A tax audit revealed certain suspicious transactions carried out between Oasmia and the companies Alceco International S.A. and Ardenia Investments Ltd that are controlled by Julian Aleksov and his former father-in-law, and this matter has been reported to the Swedish Economic Crime Authority.

5. Atreca Inc. (BCEL)

Atreca Inc. is a biopharmaceutical company developing novel antibody-based immunotherapeutics to treat a range of solid tumor types.

Gained 13.87% to close Tuesday's trading at $19.05.

News: No news

Recent event:

The Company went public on the Nasdaq Global Select Market on June 20, 2019, offering its shares at a price of $17.00 per share.

Pipeline and Near-term Catalysts:

The Company's lead product candidate is ATRC-101, a monoclonal antibody in preclinical development that has demonstrated reactivity with ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients.

The company expects filing an IND application for ATRC-101 in late 2019 and initiating a phase 1b clinical trial in patients with solid tumors in early 2020, subject to FDA approval of IND application.